The FDA approved Ascendis Pharma’s once‑weekly TransCon CNP (navepegritide) for achondroplasia, providing an alternative treatment option in a competitive therapeutic area. The approval sets the stage for market entry where multiple companies are vying for share in a rare pediatric indication. Ascendis’ TransCon prodrug technology and weekly dosing profile are expected to differentiate commercially. The approval also triggers payer, supply‑chain and pediatric‑care delivery planning; competitors and clinicians will monitor real‑world adoption and head‑to‑head effectiveness and safety comparisons.